Cargando…

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

Metformin has been proposed to operate as an agonist of SIRT1, a nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase that mimics most of the metabolic responses to calorie restriction. Herein, we present an in silico analysis focusing on the molecular docking and dynamic simulation of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuyàs, Elisabet, Verdura, Sara, Llorach-Parés, Laura, Fernández-Arroyo, Salvador, Joven, Jorge, Martin-Castillo, Begoña, Bosch-Barrera, Joaquim, Brunet, Joan, Nonell-Canals, Alfons, Sanchez-Martinez, Melchor, Menendez, Javier A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232372/ https://www.ncbi.nlm.nih.gov/pubmed/30459716 http://dx.doi.org/10.3389/fendo.2018.00657

Ejemplares similares

Metformin directly targets the H3K27me3 demethylase KDM6A/UTX
por: Cuyàs, Elisabet, et al.
Publicado: (2018)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer’s Disease Therapeutic Agents
por: Llorach-Pares, Laura, et al.
Publicado: (2017)

Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer’s Disease: A Computational Study
por: Llorach-Pares, Laura, et al.
Publicado: (2018)

Computer-Aided Drug Design (CADD) to De-Orphanize Marine Molecules: Finding Potential Therapeutic Agents for Neurodegenerative and Cardiovascular Diseases
por: Llorach-Pares, Laura, et al.
Publicado: (2022)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021)

Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells
por: Corominas-Faja, Bruna, et al.
Publicado: (2018)

Activation of the methylation cycle in cells reprogrammed into a stem cell-like state
por: Fernández-Arroyo, Salvador, et al.
Publicado: (2016)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity
por: Llorach-Pares, Laura, et al.
Publicado: (2020)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers
por: Cuyàs, Elisabet, et al.
Publicado: (2016)

Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2
por: Tramonti, Angela, et al.
Publicado: (2021)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Metformin: Multi-faceted protection against cancer
por: Del Barco, Sonia, et al.
Publicado: (2011)

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers
por: Pérez-Sánchez, Almudena, et al.
Publicado: (2019)

Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study
por: Riera-Borrull, Marta, et al.
Publicado: (2017)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
por: Menendez, Javier A., et al.
Publicado: (2014)

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
por: Lopez-Bonet, Eugeni, et al.
Publicado: (2019)

Metformin and cancer: Quo vadis et cui bono?
por: Menendez, Javier A., et al.
Publicado: (2016)

Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2016)

Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome
por: Menendez, Javier A., et al.
Publicado: (2016)

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
por: Martin-Castillo, Begoña, et al.
Publicado: (2018)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_25dk9s3cefcivf9k84jo9qmdjd